Objective: To observe the short-term and long-term influences of nasal continuous positive airway pressure (nCPAP) to sleep architecture of obstructive sleep apnea hypopnea syndrome (OSAHS).
Methods: Thirty cases who were diagnosed as OSAHS patients by polysomnography (PSG) were enrolled in the study. They received the nCPAP treatment in hospital at first night and then at home. Seventeen healthy adults were enrolled as control group and experienced PSG monitoring and recording. The sleep architectures of control group and OSAHS group (before nCPAP, first night on the nCPAP and 6 months after continuous nCPAP treatment) were analysed.
Results: The sleep shift number, first stage sleep, second stage sleep, stage of slow wave sleep and stage of rapid eye movement (REM) sleep were 34.41 +/- 10.16, (5.95 +/- 3.89)%, (48.13 +/- 7.68)%, (18.30 +/- 4.71)%, and (26.83 +/- 6.65)%, respectively, in control group. These parameters in OSAHS group before nCPAP were 207.30 +/- 149.80, (21.42 +/- 10.17)%, (55.24 +/- 13.28)%, (15.38 +/- 19.57)%, and (10.15 +/- 7.82)%, respectively. At the first night of nCPAP treatment they were 55.77 +/- 25.04, (10.92 +/- 9.62)%, (50.19 +/- 13.34)%, (17.53 +/- 10.06)%, and (21.17 +/- 7.66)%, respectively. There were statistically significant differences between the PSG parameters before and after nCPAP treatment in OSAHS group (P < 0.05). After 6 months of nCPAP treatment, the stage of REM sleep was significantly shorter (P < 0.05), but the other parameters had no significant changes compared with those at the first night on nCPAP (P > 0.05).
Conclusion: The sleep shift number and first stage sleep in OSAHS group were significantly increased, but the stage of REM sleep was significantly decreased than those in control group. The sleep architecture of OSAHS was significantly improved when the nCPAP treatment was given continuously.
Download full-text PDF |
Source |
---|
BMJ Open
January 2025
Division of Neonatal Medicine, Department of Paediatrics and Child Health, University of Nairobi School of Medicine, Nairobi, Kenya.
Background: Respiratory Distress Syndrome (RDS) is the most common complication of preterm neonates. It remains one of the major public health concerns that contribute to neonatal mortality and morbidity, especially in Africa, where 80% of neonatal mortality is estimated to be caused by preterm complications. Nasal Continuous Positive Airway Pressure (NCPAP) ventilation is the preferred mode of RDS treatment.
View Article and Find Full Text PDFBMC Pediatr
November 2024
Division of Neonatology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tzyou 1st Road Kaohsiung 807, Kaohsiung, Taiwan.
Background: Nasal continuous positive airway pressure (NCPAP) is widely used for premature infants with respiratory distress syndrome (RDS). A high-flow nasal cannula (HFNC) provides positive end-expiratory pressure using high-flow oxygen; however, the variability in distending pressure is a primary concern. This study evaluated the feasibility and safety of a newly designed protocol for NCPAP weaning with cyclic HFNC use for premature infants.
View Article and Find Full Text PDFAm J Physiol Gastrointest Liver Physiol
December 2024
Neonatal Respiratory Research Unit, Departments of Pediatrics and Pharmacology-Physiology, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Gastroesophageal refluxes (GERs) are universal in newborns and may induce deleterious consequences, especially in preemies. We have previously shown that nasal continuous positive airway pressure (nCPAP) inhibits GERs in full-term lambs, complementing similar results in adult humans. The effect of high-flow nasal cannula (HFNC) on GERs, however, remains unknown.
View Article and Find Full Text PDFAdv Respir Med
October 2024
Neonatal Research Center, Mashhad University of Medical Sciences, Mashhad 91388-13944, Iran.
Background: The aim of this study is to investigate and compare the effects of administering a surfactant through a fine intra-tracheal catheter during spontaneous breathing with the usual INSURE method in premature infants.
Materials And Methods: In this clinical trial, premature babies with respiratory distress syndrome who required surfactant administration were randomly assigned to two groups: an intervention group (MIST) and a control group (INSURE). The treatment results were compared in terms of complications related to treatment (desaturation, apnea, bradycardia, and surfactant reflux), respiratory complications (requirement for mechanical ventilation, duration of nCPAP, duration of oxygen requirement, frequency of pneumothorax, and pulmonary hemorrhage), complications related to prematurity (incidence of IVH, NEC, BPD, and PDA), the need for a second dose of surfactant, and the duration of hospitalization.
J Matern Fetal Neonatal Med
December 2024
Graduate School of Nursing Sciences, Global Health Nursing, St Luke's International University, Tokyo, Japan.
Background: Noninvasive neurally-adjusted ventilatory assist (NIV-NAVA) improves patient-ventilator synchrony and may reduce treatment failure in preterm infants compared with nasal continuous positive airway pressure (NCPAP) and noninvasive positive-pressure ventilation (NIPPV). We conducted a systematic review and meta-analysis to assess the effects of NIV-NAVA in preterm infants with respiratory distress.
Methods: Four investigators independently assessed the eligibility of studies in CENTRAL, CINAHL, ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!